

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 2 8 2002

Applicants

Jiangchun Xu et al.

TECH UENTER 1600/2900

Application No.

09/657,279

Filed

September 5, 2000

For

COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF PROSTATE CANCER

Art Unit

: 1643

Docket No.

: 210121.427C19

Commissioner for Patents Washington, DC 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references, as required under 37 C.F.R. § 1.98, are enclosed). Documents AP and AQ on the attached Form PTO-1449 were cited in a Search Report for corresponding foreign application PCT/US00/30904, mailed September 25, 2001, a copy of which is enclosed. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Second Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.



JEH:mls

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031 Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Jeffrey E. Hundley, Ph.D. Registration No. 42,676

2